VAXCHORA Pediatric Study
Status: | Active, not recruiting |
---|---|
Conditions: | Infectious Disease |
Therapuetic Areas: | Immunology / Infectious Diseases |
Healthy: | No |
Age Range: | 2 - 17 |
Updated: | 7/27/2018 |
Start Date: | July 21, 2017 |
End Date: | October 2020 |
A Phase 4 Study to Assess the Safety and Immunogenicity of VAXCHORA (Cholera Vaccine, Live, Oral) in Children 2 to <18 Years of Age
VAXCHORA (Cholera Vaccine, Live, Oral) is a vaccine indicated for active immunization against
disease caused by Vibrio cholerae serogroup O1. VAXCHORA is approved for use in adults 18
through 64 years of age travelling to cholera-affected areas. The primary goals of this Phase
4 study is to evaluate the safety and immunogenicity of VAXCHORA in children ages 2 years to
<18 years of age in developed countries.
disease caused by Vibrio cholerae serogroup O1. VAXCHORA is approved for use in adults 18
through 64 years of age travelling to cholera-affected areas. The primary goals of this Phase
4 study is to evaluate the safety and immunogenicity of VAXCHORA in children ages 2 years to
<18 years of age in developed countries.
Inclusion Criteria:
- Male or Female
- Between 2 and <18 years of age on Day 1
- In general good health
- Able and willing to provide informed assent for study participation
- Primary caregiver is able and willing to provide informed consent for study
participation
- (for females of childbearing potential) Using an acceptable method of contraception
through Day 29
Exclusion Criteria:
- Current acute gastrointestinal illness or loose stools within 3 days of Day 1 visit
- Current acute febrile illness
- History of cholera infection
- History of cholera vaccination
- History of severe allergic reaction (e.g. anaphylaxis) to any ingredient of VAXCHORA
- Congenital or acquired immunodeficiency
- Pregnancy (for females of childbearing potential)
- Any other condition that, in the opinion of the Investigator, creates an unacceptable
risk to the subject
- Any other condition that, in the opinion of the Investigator, will interfere with the
conduct of the study or the validity of the data
- Duration of >2 weeks of abnormal stool pattern, defined as <3 stools per week or >2
stools per day in the past 6 months
- Regular use of laxatives in the past 6 months
- History of enterotoxigenic E. coli infection
- Travel to cholera-endemic area in the previous 5 years
- Nursing/Breastfeeding
- Received or plans to receive the following from 14 days prior to the study vaccination
through 11 days after vaccination: Any other licensed vaccines, antibiotics, or
chloroquine
- Received or plans to receive any other investigational agent throughout the main study
(Day 181)
We found this trial at
10
sites
201 Dowman Dr
Atlanta, Georgia 30303
Atlanta, Georgia 30303
(404) 727-6123
Principal Investigator: Evan Anderson, MD
Phone: 404-727-3769
Emory University Emory University, recognized internationally for its outstanding liberal artscolleges, graduate and professional schools,...
Click here to add this to my saved trials
1709 S Rock Rd
Wichita, Kansas 67207
Wichita, Kansas 67207
316-689-6629
Principal Investigator: Terry Klein, MD
Phone: 316-689-6685
Click here to add this to my saved trials
Boston, Massachusetts 02118
Principal Investigator: Elizabeth Barnett, MD
Phone: 617-414-5813
Click here to add this to my saved trials
Click here to add this to my saved trials
Kansas City, Missouri 64114
Principal Investigator: John Ervin, MD
Phone: 816-943-0770
Click here to add this to my saved trials
Lenexa, Kansas 66219
Principal Investigator: Carlos A Fierro, MD
Phone: 913-825-4405
Click here to add this to my saved trials
Lexington, Kentucky
859) 257-9000
Principal Investigator: Richard Greenberg, MD
Phone: 859-323-5015
University of Kentucky The University of Kentucky is a public, land grant university dedicated to...
Click here to add this to my saved trials
Mount Pleasant, South Carolina 29464
Principal Investigator: Cynthia Strout, MD
Phone: 843-856-5141
Click here to add this to my saved trials
Nashville, Tennessee 37203
Principal Investigator: Stephen Sharp, MD
Phone: 615-329-0197
Click here to add this to my saved trials
Rochester, New York 14609
Principal Investigator: Matthew G Davis, MD
Phone: 585-288-0890
Click here to add this to my saved trials